Rising incidence of second cancers in patients with low‐risk (T1N0) thyroid cancer who receive radioactive iodine therapy

American Thyroid Association guidelines currently recommend the selective use of radioactive iodine (RAI) therapy in patients with well differentiated thyroid cancer (WDTC). Despite these guidelines, RAI ablation has been used routinely in all but the very lowest risk patients with thyroid cancer over the last 30 years. The objective of this study was to evaluate patterns of RAI use and elevated risk of secondary primary malignancies (SPM) in patients with low‐risk (T1N0) WDTC.

[1]  M. Gapany.  The Effectiveness of Radioactive Iodine for Treatment of Low-Risk Thyroid Cancer: A Systematic Analysis of the Peer-Reviewed Literature from 1966 to April 2008 , 2011 .

[2]  John T. Chang,et al.  The effectiveness of radioactive iodine for treatment of low-risk thyroid cancer: a systematic analysis of the peer-reviewed literature from 1966 to April 2008. , 2010, Thyroid : official journal of the American Thyroid Association.

[3]  H. Welch,et al.  Overdiagnosis in cancer. , 2010, Journal of the National Cancer Institute.

[4]  C. Silver,et al.  Thyroid incidentalomas: to treat or not to treat , 2010, European Archives of Oto-Rhino-Laryngology.

[5]  D. Nostrand.  The Benefits and Risks of I-131 Therapy in Patients with Well-Differentiated Thyroid Cancer , 2009 .

[6]  Stephanie L. Lee,et al.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. , 2009, Thyroid : official journal of the American Thyroid Association.

[7]  S. Straus,et al.  Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis. , 2009, Thyroid : official journal of the American Thyroid Association.

[8]  L. Kowalski,et al.  Clinical predictors of quality of life in patients with initial differentiated thyroid cancers. , 2009, Archives of otolaryngology--head & neck surgery.

[9]  P. Bourgeois.  A Proposition for the Use of Radioiodine in WDTC Management , 2009, Journal of Nuclear Medicine.

[10]  Xiao-Cheng Wu,et al.  Annual Report to the Nation on the Status of Cancer, 1975–2005, Featuring Trends in Lung Cancer, Tobacco Use, and Tobacco Control , 2008, Journal of the National Cancer Institute.

[11]  W. Oyen,et al.  Guidelines for radioiodine therapy of differentiated thyroid cancer , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[12]  R. Tuttle,et al.  Medical management of thyroid cancer: a risk adapted approach , 2008, Journal of surgical oncology.

[13]  F. Vathaire.  The carcinogenic effects of radioiodine therapy for thyroid carcinoma , 2008, Nature Clinical Practice Endocrinology &Metabolism.

[14]  J. Tward,et al.  The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. , 2008, The Journal of clinical endocrinology and metabolism.

[15]  E. Mazzaferri,et al.  Increasing Incidence of Thyroid Cancer in the United States, 1973–2002Davies L, Welch HG (Dept of Veterans Affairs Med Ctr, White River Junction, Vt; Darmouth Med School, Hanover, NH) JAMA 295:2164–2167, 2006§ , 2007 .

[16]  Louise Davies,et al.  Increasing incidence of thyroid cancer in the United States, 1973-2002. , 2006, JAMA.

[17]  M. McBride,et al.  Second primary cancers in thyroid cancer patients: a multinational record linkage study. , 2006, The Journal of clinical endocrinology and metabolism.

[18]  S. Chow.  Side Effects of High-dose Radioactive Iodine for Ablation or Treatment of Differentiated Thyroid Carcinoma , 2005 .

[19]  N. Carrasco,et al.  Advances in Na+/I− symporter (NIS) research in the thyroid and beyond , 2003, Molecular and Cellular Endocrinology.

[20]  P. Hall,et al.  Second primary malignancies in thyroid cancer patients , 2003, British Journal of Cancer.

[21]  B. Hankey,et al.  The surveillance, epidemiology, and end-results program database as a resource for conducting descriptive epidemiologic and clinical studies. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  S. Mandel,et al.  Radioactive iodine and the salivary glands. , 2003, Thyroid : official journal of the American Thyroid Association.

[23]  A. Oberg,et al.  Papillary Thyroid Carcinoma Managed at the Mayo Clinic during Six Decades (1940–1999): Temporal Trends in Initial Therapy and Long-term Outcome in 2444 Consecutively Treated Patients , 2002, World Journal of Surgery.

[24]  Amy Y. Chen,et al.  The development of breast carcinoma in women with thyroid carcinoma , 2001, Cancer.

[25]  M. Schlumberger,et al.  Papillary and follicular thyroid carcinoma. , 1998, The New England journal of medicine.

[26]  C. Kirsch,et al.  Intermediate and long-term side effects of high-dose radioiodine therapy for thyroid carcinoma. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[27]  C. Begg,et al.  Methodology for evaluating the incidence of second primary cancers with application to smoking-related cancers from the Surveillance, Epidemiology, and End Results (SEER) program. , 1995, American journal of epidemiology.

[28]  S. Jhiang,et al.  Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. , 1994, The American journal of medicine.

[29]  M. Brennan,et al.  Radiation-associated sarcoma of bone and soft tissue. , 1992, Archives of surgery.

[30]  C. Blomqvist,et al.  Postirradiation sarcoma. Analysis of a nationwide cancer registry material , 1991, Cancer.

[31]  A. Neugut,et al.  Clinical Aspects of Postirradiation Sarcomas1 , 1988 .

[32]  A. Neugut,et al.  Clinical aspects of postirradiation sarcomas. , 1988, Journal of the National Cancer Institute.

[33]  M. Myers,et al.  Statistical methods for studying multiple primary malignant neoplasms , 1977, Cancer.

[34]  S. Warren.  Multiple primary malignant tumors. A survey of the literature and a statistical study , 1932 .

[35]  Z. Hall.  Cancer , 1906, The Hospital.